Revised forecast
Fiscal year ending August 2026 · Full yearPrevious forecast published 15 October 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The timing of orders and revenue recognition, mainly for projects for the medical industry, was pushed back to the following fiscal year or later; a gap between existing large-scale projects occurred; strategic pricing measures were taken while expanding the customer base; and selling, general and administrative expenses increased due to upfront investments in personnel recruitment and training, research and development, and other areas.
| Item | Details |
|---|---|
| Net Sales | ¥5,608 million → ¥4,657 million（-17.0%） |
| Operating profit | ¥801 million → ¥413 million（-48.4%） |
| Ordinary income | ¥828 million → ¥444 million（-46.4%） |
| Profit attributable to owners of the parent | ¥516 million → ¥272 million（-47.3%） |
| Net income per share | 155.12 yen → 81.28 yen（-47.6%） |
| Fiscal Period Covered | Fiscal year ending August 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 15 October 2025 |
| Previous-period results | Revenue: ¥5,086 million; operating profit: ¥774 million; ordinary profit: ¥870 million; net income attributable to owners of the parent: ¥600 million; earnings per share: ¥183.91 |
| Reason for the revision | The timing of orders and revenue recognition, mainly for projects for the medical industry, was pushed back to the following fiscal year or later; a gap between existing large-scale projects occurred; strategic pricing measures were taken while expanding the customer base; and selling, general and administrative expenses increased due to upfront investments in personnel recruitment and training, research and development, and other areas. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue declined because the timing of orders and revenue recognition for projects for the medical industry and other projects shifted to the following fiscal year or later, while a gap between large-scale projects also occurred. In addition, selling, general and administrative expenses increased due to upfront investments in pricing measures to expand the new customer base, personnel recruitment and training, and research and development.